Document is current
Any future updates will be listed below
-
Authors
Herranz-Bayo, Elena https://orcid.org/0009-0001-6939-2204
Chara-Velarde, Luis Enrique https://orcid.org/0000-0001-5143-7331
Cassinello-Espinosa, Javier
Gimeno-Ballester, Vicente https://orcid.org/0000-0002-9066-7903
Artal-Cortés, Ángel https://orcid.org/0000-0002-9778-706X
Moratiel-Pellitero, Alba https://orcid.org/0009-0000-9486-6793
Alcácera-López, Arancha https://orcid.org/0009-0009-8490-3744
Navarro-Expósito, Fátima
Riesco-Montes, Blanca https://orcid.org/0000-0001-9891-7586
Clemente-Andujar, Manuel
- License Information
-
More Information
Article History
Received: 25 July 2024
Accepted: 21 August 2024
First Online: 6 September 2024
Declarations
:
: LC-V: reports honoraria and support for attending meetings from Astra Zeneca, Roche, MSD, BMS, Pfizer, Boehringer Ingelheim and Janssen. AA-C: reports honoraria from Astra Zeneca and Roche. None were declared for the remaining authors.
: This study was approved by the local drug research ethics committee of each participating hospital and was conducted in accordance with the ethical standards of the Helsinki Declaration of the World Medical Association.
: Informed consent was obtained from the patients.
